Li Yang

Research Professor, Doctoral supervisor
lyang@bjmu.edu.cn
Xueyuan Road 38, Haidian District, Beijing, China
Peking University

Personal profile

I graduated from the School of Public Health, West China Medical University with a Bachelor's degree in Preventive Medicine in 1996, a Master's degree from the same school in 1999, and a PhD from the School of Public Health, Fudan University in 2004. Postdoctoral Fellow at the University of Vienna in Austria in 2009, Visiting Scholar at Harvard Medical School in 2010-2011.

I’m currently serving as the Deputy Director of the Department of Health Policy and Management at the School of Public Health, Peking University, as well as a member of the Expert Group on Pharmaceutical Pricing and Tendering Procurement of the National Health Security Administration, a member of the National Nutrition and Health Expert Committee, an Executive Director of the Chinese Society of Health Economics and Vice Chairman of the Medical Insurance Professional Committee, an Executive Member of the Medical Security Special Committee of the Chinese Society of Social Security, a member of the Pharmaceutical Economics Special Committee of the Chinese Pharmaceutical Association, and the Deputy Leader of the Health Technology Evaluation and Economic Policy Group of the Birth Defects Prevention and Control Special Committee of the Chinese Preventive Medicine Association. Hosted over 80 research projects funded by the National Natural Science Foundation of China, the National Social Science Foundation of China, the Beijing Natural Science Foundation, the Ministry of Science and Technology, the Ministry of Education, the National Health Commission, and the Chinese Medical Board (CMB). Published over 160 papers as the first or responsible author in domestic and international academic journals. Also served as an editorial board member for "China Health Economics", "Health Development and Policy Research", and a member of the Academic Guidance Committee for "Health Economy Research". Deputy Editor in Chief of National "14th Five Year Plan" Textbooks, Editor in Chief or Participated in the Compilation of Over 10 Textbooks and Essays.

Main research directions

Public health economics and policy, pharmaceutical economics and policy, optimization layout and planning of health resources, public health emergency management, health economics and health reform, etc.

Representative scientific research projects

1. National Natural Science Foundation of China General Project: Research on Value based Public Health Project Evaluation Tools, Spatial Allocation, and Optimization from an Integrated Perspective, 2022-2025, PI.

2. Major Project of National Social Science Fund: Research on the Collaborative Development and Governance of Healthcare, Medical Insurance, and Medicine under the Background of Deepening Medical Reform, 2024-2026, Co-PI.

3. Beijing Natural Science Foundation: Simulation and Optimization Research on Resource Allocation of Fever Outpatient Department in Beijing, and Early Warning and Emergency Response Combining Peace and War. Responsible person for 2022-2023,PI.

4. National Key Research and Development Program of the Ministry of Science and Technology: Establishment and Health Economic Evaluation of the Combined Early Screening Model for Common Malignant Tumors 2021-2024, Key investigator.

5. National Health Commission: Research on the Health Status and Health Service Utilization of Children and Adolescents in China, 2023-2024, PI.

6. Beijing National Health Commission: Research on modernization of Beijing medical service planning system and mechanism 2021-2022, PI.

7. National Health Commission: Research on the Scope and Subsidy Standards of Basic Public Health Services in the Post Pandemic Era 2021, PI.

8. Capital Development Fund Project: Research on emergency response and normalized protective measures of medical institutions for the COVID-19,2021, sub PI.

9. International cooperation of the National Natural Science Foundation of China: Economic evaluation based on big data breast cancer gene detection 2019-2020, PI.

10. China Medical Foundation (CMB): China breast cancer gene technology value assessment 2020-2022，PI.

11. National Natural Science Foundation of China: Research on the Establishment and Analysis Paradigm of National Drug Policy Monitoring Indicator System Based on Big Data, 2017-2020, PI.

12. National Natural Science Foundation of China: Long term Impact Tracking Study on the Utilization of Medical Services and Rational Use of Drugs under the National Essential Medicines System, 2013-2016, PI.

13. National Health and Family Planning Commission: Drug Policy Implementation Monitoring Indicator System and Monitoring Research 2015, PI.

14. Humanities and Social Sciences Project of the Ministry of Education: Research on the Implementation Effect of Basic Drugs Based on the New Rural Cooperative Medical Scheme 2011-2013, PI.

15. National Natural Science Foundation of China Youth Fund: Research on the Impact of Chronic Diseases on Rural Economic Development and Health Investment Strategies from 2006 to 2008, PI.

10 representative papers

1. Zhang J, Xu Z, Wei X, Fu Y, Zhu Z, Wang Q, Wang Q, Liu Q, Guo J, Hao Y, Yang L*. Analysis of health service utilization and influencing factors due to COVID-19 in Beijing: a large cross-sectional survey. Health Res Policy Syst. 2024;22(1):31.

2. Wang Q, Liu S, Nie Z, Zhu Z, Fu Y, Zhang J, Wei X, Yang L*, Wei X. The pan-Canadian Tiered Pricing Framework and Chinese National Volume-Based Procurement: A comparative study using Donabedian’s structure-process-outcome framework. J Glob Health 2023;13:04137.

3. Zhu Z, Wang Q, Sun Q, Lexchin J and Yang L*. Improving access to medicines and beyond: the national volume-based procurement policy in China. BMJ Glob Health 2023;8:e011535.

4. Fu Y, Zhao J, Han P, Yang L*,Ren T, Zhan S,Li L. Cost-effectiveness of COVID-19 vaccination: A systematic review. J Evid Based Med. 2023;1-14.

5. Sun L, Wei X., Manchanda, R., Legood, R. , & Yang L*.. Using genetic testing at cancer diagnosis for breast cancer control. China CDC weekly, 2022. 4(32), 4.

6. Wei X, Zhao J , Yang L* . Cost-effectiveness of new antiviral treatments for non-genotype 1 hepatitis C virus infection in China: a societal perspective[J]. BMJ Global Health, 2020, 5(11):e003194.

7. Sun L, Sadique Z, dos-Santos-Silva I, Yang L*, Legood R. Cost-effectiveness of breast cancer screening programme for women in rural China. International journal of cancer, 2019;144（10）：2586-2604.

8. Sun L, Legood R, Sadique Z, dos-Santos-Silva I, Yang L*. Cost–effectiveness of risk-based breast cancer screening programme, China. Bulletin of the World Health Organization 2018;96：568-577.

9. Wen lk, Wu JJ, Fen L, Yang L*, Qian F. Comparing the economic burden of ischemic stroke patients with and without atrial fibrillation: a retrospective study in Beijing, China. Current Medical Research and Opinion，2017,33(10): 1789-1794.

10. Yang, L#, Sun, L., Wen, L. et al. Financing strategies to improve essential public health equalization and its effects in China. Int J Equity Health. 2016;15(194).